Open AccessNon-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana
Author(s) -
Carolyn Wester,
Ann Thomas,
Hermann Bussmann,
Sikhulile Moyo,
Joseph Makhema,
Tendani Gaolathe,
Vladimir Novitsky,
Max Essex,
Victor DeGruttola,
Richard Marlink
Publication year - 2010
Publication title -
aids
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/01.aids.0000366080.91192.55
Subject(s) - nucleoside reverse transcriptase inhibitor , reverse transcriptase inhibitor , antiretroviral therapy , reverse transcriptase , virology , medicine , didanosine , human immunodeficiency virus (hiv) , nucleoside analogue , nucleoside , sida , lentivirus , viral disease , viral load , biology , polymerase chain reaction , genetics , gene
National initiatives offering non-nucleoside reverse transcriptase inhibitor (NNRTI)-based combination antiretroviral therapy (cART) have expanded in sub-Saharan Africa. The Tshepo study is the first clinical trial evaluating the long-term efficacy and tolerability of efavirenz versus nevirapine-based cART among adults in Botswana.